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Abstract
Introduction: Characterization of novel proteins in maternal serum derived from
mothers carrying Down syndrome (DS) fetuses.
Material and methods: Based on last comparative proteomic analysis, five 
significant differences of expressed proteins in serum from four groups have
been confirmed by ELISA. DAVID and GeneGo MetaCore were used to bioinfor-
matically analyze candidate protein markers.
Results: The serum levels of ceruloplasmin (CP) and complement factor B (CFB)
were significantly increased in mother carried DS fetuses (346.5 ng/ml and 466.8
ng/ml vs. 248.6 ng/ml and 293.5 ng/ml, p< 0.05). Twenty-nine proteins were
mainly categorized into binding, catalytic activity and enzyme regulator activi-
ty proteins, and their biological roles were involved in biological regulation, meta-
bolic processes, cellular processes, and response to stimuli. The immune response
alternative complement pathway was the most significant GeneGo Pathway
related to DS. 
Conclusions: These 29 proteins have relations with the development of Down
syndrome, especially CP and CFB play more important roles.
Key words: Down syndrome, proteomic, serum, bioinformatics, biomarkers, pre-
natal diagnosis.
Introduction
It is well known that prenatal screening and diagnosis for Down syn-
drome (DS) are important for prepotency. They have been widely used in
pregnant women all around the world in the past 25 years. Nowadays, the
main methods of prenatal screening are screening in the second trimester
[1], screening in the first trimester [2] and integrated screening [3]. The
biomarkers associated with DS which have been reported previously
include α-fetoprotein (AFP), unconjugated estriol (uE3), free β subunit of
human chorion gonadotrophin (fβhCG), pregnancy-associated plasma pro-
tein A (PAPP-A), disintegrin and metalloprotease 12 (ADAM-12), superox-
ide dismutase 1 (SOD1), and so on [4]. However, all of these markers still
could not be sufficient, because they only achieved a detection rate of 
50–85% at a 5% false-positive rate [5-8]. Not only will many pregnant
women carrying DS fetuses miss diagnosis, but also some will be offered
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invasive and risky diagnostic procedures. Therefore,
prenatal medical experts are increasingly focusing
on discovery of new biomarkers which can improve
the efficiency of DS screening.
In recent years, proteomic studies have proved
to be a powerful platform for biomarker discovery,
and the identified new biomarkers will revolution-
ize diagnostics for many diseases [9-13]. Nagalla 
et al. [14] attempted to identify potential serum 
biomarkers to detect DS by a comprehensive pro-
teomic analysis firstly. However, similar studies
based on maternal blood have been limited [14-17].
The protein biomarkers reported by these studies
were not always reproducible at the same time.
Hence, it is important to improve the research on
application of proteomics in DS. 
In our previous study, we used 2-DE and MS to
identify the different proteins for DS in maternal
serum, and successfully identified 29 protein bio-
markers [18]. Moreover, we also found that TF, DES,
SERPINA1, CP, APCS, CFB, C4A, CPN1, CFHR1 and PLG
were noteworthy for further study, because they
showed the most significant changes. Although
some reports have indentified some proteins in
maternal serum which were considered as new DS
markers, these proteins have not been analyzed by
bioinformatics methods. Thus we used bioinfor-
matics analysis to determine whether these 29 pro-
teins are related to the aetiology and function of DS. 
This work describes the biochemical character-
istics of novel proteins in maternal serum from
mothers carrying DS fetuses, and explores their
complicated interrelations. By ELISA, we aimed to
detect the serum concentration of 5 proteins which
showed the most significant differential expression,
and carry out bioinformatics analysis using DAVID
and MetaCore.
Material and methods
The study design and protocol were reviewed
and approved by the ethics committee of Chang  -
zhou Woman and Children Health Hospital affiliat-
ed to Nanjing Medical University.
Samples collection
The maternal serum was collected from 11 preg-
nant women carrying a DS fetus and 10 controls
with a normal fetus. They all entered the system of
prenatal screening in Changzhou Women and Chil-
dren Health Hospital from April 2008 to June 2010.
The mothers with DS were prenatally diagnosed by
the karyotype analysis of fetal cells from AF
obtained by amniocentesis between gestational
weeks 16 and 21. Ten women with normal fetuses
were selected as the control group. The match con-
ditions of cases and the control group were: 1) age
< 1 year, 2) gestational weeks < 7 days. 
Eleven DS patients (2 days – 3 months) and 10
control subjects (3 days – 1 month) underwent rou-
tine clinical and laboratory evaluation. All DS
patients examined were confirmed to possess the
chromosome abnormality (trisomy 21). Control sub-
jects had no previous history of neurological deficits
or any serious disorder. 
Three millimetres blood samples of all the cas-
es were collected by simple needle aspiration. The
samples were centrifuged at 3000 rpm for 5 min to
remove cells. The serum was stored at –86°C until
further analysis. 
Methods
2DE-MS and protein identification
Firstly, we depleted high-abundance proteins in
serum, including albumin, IgG, and so on. Then, 
2-DE and MS were used to identify the proteins for
DS in maternal serum. Twenty-nine proteins were
identified successfully in the end. The methods of
2-DE, MS and protein identification were performed
as in our report [18]. 
ELISA
Among the 29 protein biomarkers, we selected
5 proteins to detect their serum concentration. They
were Ceruloplasmin (CP, P00450), Complement fac-
tor H-related protein 1 (CFHR1, Q03591), Comple-
ment factor B (CFB, P00751), Desmin (DES, P17661)
and Plasminogen (PLG, P00747). 
Enzyme-linked immunosorbent assays for these
5 proteins were based on the non-competitive
sandwich ELISA method using commercially avail-
able kits purchased from R&D, USA. The main pro-
tocol was performed as described previously [19]. 
Bioinformatics analysis
DAVID (http://david.abcc.ncifcrf.gov/, version:
6.7) [20, 21] was used to process the bioinformat-
ics analysis of these candidate protein markers,
including protein classification (based on Biological
Process Ontology and Molecular Function Ontology,
respectively), enrichment analysis for significant
gene ontology categories, KEGG (Kyoto Encyclope-
dia of Genes and Genomes) pathway mapping and
significant pathway computing, and so on. GeneGo
MetaCore (http://www.genego.com, version: 6.5)
[22] was used to analyze the pathways of these pro-
teins and related genes. At the same time, we gen-
erated biological association networks with Meta-
Core.
Statistical analysis
All data were collected and statistically analyzed
using SPSS 13.0 software. Results of parameters
were expressed as mean and SD. We compared dif-Arch Med Sci 2, April / 2012 185
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ferences in serum level of proteins by means of
the t statistic. A value of p less than 0.05 was con-
sidered to be statistically significant.
Results
Differential expression of five proteins
A total of 29 proteins were identified success-
fully in maternal serum coming from DS cases com-
pared with the control group, including 14 proteins
that were up-regulated, while 15 proteins were
decreased (Table I). More results of the 29 proteins
were descried in our last study [18]. In the present
study, we selected 5 proteins for further analysis,
including CP, CFHR1, CFB, DES and PLG. Their entry
name, protein name, molecular weight (MW), PI,
score, coverage, expect and the fold change of
expression density are shown in Table II.
Serum concentration
In order to verify the results of 5 proteins as iden-
tified by MALDI-TOF-TOF/MS, we detected the serum
concentrations of them by ELISA. Table III shows the
ELISA results of 5 proteins in the four groups.
Compared with women with normal fetuses, the
serum levels of CP and CFB were significantly
increased in mothers carrying DS fetuses (p < 0.05).
The mean concentrations were 346.5 ng/ml and 466.8
ng/ml respectively, vs. 248.6 ng/ml and 293.5 ng/ml
in the control group, respectively (Figures 1 A, D). 
There were no significant differences in the amount
Gene names Entry name Accession Protein names
A1BG A1BG_HUMAN P04217 α1B-glycoprotein
AFM AFAM_HUMAN P43652 Afamin
AMBP AMBP_HUMAN P02760 Protein AMBP
APCS SAMP_HUMAN P02743 Serum amyloid P-component
APOA1 APOA1_HUMAN P02647 Apolipoprotein A-I
APOH APOH_HUMAN P02749 β2-glycoprotein 1
C4A CO4A_HUMAN P0C0L4 Complement C4-A
CFB CFAB_HUMAN P00751 Complement factor B
CFH CFAH_HUMAN P08603 Complement factor H
CFHR1 FHR1_HUMAN Q03591 Complement factor H-related protein 1
CFHR2 FHR2_HUMAN P36980 Complement factor H-related protein 2 
CFI Q8WW88_HUMAN Q8WW88 CFI protein
CLU CLUS_HUMAN P10909 Clusterin
CP CERU_HUMAN P00450 Ceruloplasmin
CPN1 CBPN_HUMAN P15169 Carboxypeptidase N catalytic chain
DES DESM_HUMAN P17661 Desmin
GC VTDB_HUMAN P02774 Vitamin D-binding protein 
GRIN1 GRIN1_HUMAN Q7Z2K8 G protein-regulated inducer of neurite outgrowth 1
HPX HEMO_HUMAN P02790 Hemopexin
KLC2 KLC2_HUMAN Q9H0B6 Kinesin light chain 2
LRG1 A2GL_HUMAN P02750 Leucine-rich α2-glycoprotein
MASP2 MASP2_HUMAN O00187 Mannan-binding lectin serine protease 2
PEPD PEPD_HUMAN P12955 Xaa-Pro dipeptidase
PLG PLMN_HUMAN P00747 Plasminogen
RIMS3 RIMS3_HUMAN Q9UJD0 Regulating synaptic membrane exocytosis protein 3
SERPINA1 A1AT_HUMAN P01009 α1-antitrypsin
TF TRFE_HUMAN P02787 Serotransferrin
VTN VTNC_HUMAN P04004 Vitronectin
ZNF485 ZN485_HUMAN Q8NCK3 Zinc finger protein 485
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of CFHR1, DES and PLG between the two groups 
(p> 0.05) (Figures 1 B, C, E). However, the levels of CP,
CFB, DES and CFHR1 were decreased in DS patients.
There were significant difference between DS patients
and normal babies (p < 0.05). Especially, CP and CFB
were significantly reduced (p < 0.001). The level of
PLG still had no significant changes (p > 0.05).
Gene ontology analysis
By DAVID, 29 proteins were mapped to at least
one annotation term within the GO molecular func-
tion category, including 40 (53.3%) binding proteins,
9 proteins (12.9%) with catalytic activity, 8 proteins
(10.7%) with hydrolase activity, 5 proteins (6.7%)
with enzyme regulator activity, 5 proteins (6.7%)
with transporter activity, and 9 others (12.0%),
including proteins with signal transducer activity,
receptor activity, motor activity, oxidoreductase
activity, structural molecule activity, and ion trans-
membrane transporter activity, as shown in Figure
2 A. On the other hand, they were also mapped
within the GO biological process category: biologi-
cal regulation (18, 13.5%), metabolic process (18,
13.5%), cellular process (18, 13.5%), response to
stimulus (15, 11.3%), establishment of localization
(11, 8.3%), localization (11, 8.3%), immune system
process (8, 6.0%), multicellular organismal process
(8, 6.0%), developmental process (7, 5.3%), cellular
component organization (6, 4.5%) and other 
proteins (13, 9.8%) related to the categories of mul-
ti-organism process, biological adhesion, death, cel-
lular component biogenesis, locomotion, reproduc-
tive process, reproduction, and growth, as shown
in Figure 2 B.
KEGG pathway qnalysis
Relating the gene symbol of these proteins to
the KEGG GENE ID, a total of 12 proteins corre-
sponded to 15 pathways of KEGG, of which the
pathway of Complement and coagulation cascades
was the most significantly enriched. There were 
7 proteins participating in the pathway: C4A, CFB,
CFAH, CFI, MASP2, PLG and SERPINA1.
Enrichment analysis
Enrichment analysis consists of matching gene
IDs of proteins in functional ontologies by Meta-
Core. The probability of a random intersection
between a set of IDs the size of the target list with
ontology entities was estimated with the p value
of the hypergeometric intersection. A lower p val-
ue means higher relevance of the entity to the
dataset, which shows in higher rating for the enti-
ty. All maps were drawn by GeneGo. The height of
the histogram corresponded to the relative expres-
sion value for a particular gene/protein.
The top three most significant GeneGo Pathway
Maps were: 1) Immune response_Alternative com-
plement pathway, 2) Immune response_Lectin
induced complement pathway, and 3) Blood coag-
ulation_Blood coagulation (Figure 3 A). Meanwhile,
protein activation cascade, complement activation
and regulation of response to stimulus were the
Entry name  MWP I Score Coverage Fold change Expect
CFAB_HUMAN 86847 6.67 264 43% 17.5/0 2.70E-22
FHR1_HUMAN 38766 7.38 82 31% 1.0/0 0.00045
CERU_HUMAN 122983 5.44 119 21% 5.43 8.60E-08
DESM_HUMAN 32382 4.97 78 39% 7.0 0.001
PLMN_HUMAN 15776 8.73 92 44% 0.7/0 3.90E-05
Table II. Five proteins differentially expressed in serum of mothers with DS fetuses
n CP [ng/ml] DES [nmol/l] PLG [ng/ml] CFB [ng/ml] CFHR1 [ng/ml]
Mothers with DS fetuses 11 346.5 ±111.81 21.1 ±13.5 2.1 ±1.3 466.8 ±216.41 109.0 ±35.5
Mothers with normal fetuses 10 248.6 ±78.3 20.1 ±11.7 1.7 ±1.2 293.5 ±75.0 88.6 ±51.9
t 2.301 0.191 0.786 2.400 1.058
P 0.033 0.851 0.442 0.027 0.303
DS patients 11 166.1 ±55.02 6.5 ±2.31 0.9 ±0.4 174.3 ±55.02 44.6 ±17.41
Normal babies 10 244.0 ±36.0 12.3 ±7.8 0.9 ±0.4 311.8 ±102.4 67.4 ±15.2
t –3.873 –2.273 –0.608 –3.776 –3.218
P 0.001 0.035 0.550 0.001 0.005
Table III. Serum concentrations of proteins by ELISA
1compared with control group p < 0.05, 2compared with control group p < 0.001Arch Med Sci 2, April / 2012 187
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most significant enriched GO processes of the pro-
teins (Figure 3 B). With the Disease folders, repre-
senting over 500 human diseases annotated 
by GeneGo, these 29 proteins were mainly related
to eye diseases and some kinds of heart diseases 
(Figure 3 C). 
Network connectivity analysis
GeneGo MetaCore was used to generate bio-
logical association networks. A total of 15 relevant
networks were constructed. The one with the high-
est score is shown in Figure 4, which was consti-
tuted by 6 proteins with direct interaction. 
The 6 proteins were PLG, APOH, Vitronectin, Car-
boxypeptidase N (cat), α1-antitrypsin and A1M. The
PLG was the center of the network. 
Discussion
Two-dimensional (2-D) gel electrophoresis and
tandem mass spectrometry (MS-MS) have been
used to search for new biomarkers, including in DS
screening and diagnosis [12, 14-17, 23-27]. But lim-
ited studies have been focused on this screening
in maternal blood [14-17]. In a past study of this lab,
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29 protein biomarkers for DS in maternal serum
were successfully identified by the two methods
[18]. The top 5 increased proteins were TF, A1BG,
DES, SERPINA1 and CP, while APCS was the most
down-regulated one. In the present study, we
selected 5 proteins (CP, CFHR1, CFB, DES and PLG)
for further analysis (bioinformatics analysis and
ELISA). The reasons why we selected them were: 
1) the degree of differential expression, 2) biologi-
cal function of protein, 3) the relationship between
protein and disease, 4) learning from published lit-
erature. Based on maternal serum, we found that
only the serum levels of CP and CFB were signifi-
cantly increased, while there were no significant
differences in the amount of CFHR1, DES and PLG.
Some studies have also reported different results
between proteomics and ELISA [28, 29]. Perhaps
the reasons were: 1) there are differences in the
detection sensitivity of the two methods between
MS and ELISA, 2) related to the small number of
samples of ELISA tests, 3) some technological lim-
itations of 2-DE and MS. Meanwhile, we found that
the levels of CP, CFB, DES and CFHR1 were signifi-
cantly decreased in DS patients, while PLG still had
no changes. Combined with the two ELISA tests,
we suggest that CP and CFB play more important
roles in DS. They might be used to improve the effi-
cacy of the prenatal screening and diagnosis of DS,
and they might relate to the disease phenotype and
molecular mechanism of DS. However, the expres-
sions of protein were inconsistent in the serum
from mothers and newborn babies. This might be
caused by the biosynthesis and metabolism of the
proteins, and it is worthy of further research.
The CP is an important iron transport protein for
physiological iron homeostasis in the brain and neu-
ronal survival [30], and it is reported to be associ-
ated with neurodegenerative disease [31]. Recent-
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ly, Perluigi et al. [32] found that oxidative damage
is an early event in DS pathogenesis and might con-
tribute to the development of deleterious DS phe-
notypes. Moreover, its expression is adjusted by
SOD1 [33], which is located on chromosome 21.
Complement factor B (CFB, P00751) plays an impor-
tant role in the alternative pathway for complement
activation. Strohmeyer et al. [34] reported that CFB
was present in the frontal cortex of AD patients,
and was significantly increased, indicating alterna-
tive pathway activation. It suggested that condi-
tions conducive to chronic alternative pathway acti-
vation may exist in the AD brain. Furthermore, as
a temporal model for studying the development of
AD, the brain in DS often had similar changes as in
AD brain [35]. According to our study, both the 
2 proteins seemed associated with the brain dam-
age of DS, but the exact mechanisms need further
research.
Pathway and network analyses in this study
related the immune response alternative comple-
ment pathway to DS. Some previous studies have
also reported that there were relationships between
DS and the complement system [36, 37]. For exam-
ple, C1q was positive in DS cases and was associ-
ated with activated microglia. It provides evidence
for antibody-mediated inflammatory factors con-
tributing to the rapid accumulation of neu-
ropathology in DS brain [36]. It was very interest-
ing that we first found CFB also to be associated
with DS. Surprisingly, the enrichment analysis of
differentially expressed proteins in DS using the
MetaCore database showed the most strongly relat-
ed disease to be eye diseases and some kinds of
heart diseases. About 3% of DS newborns are asso-
ciated with cataract, and the rate of congenital
heart disease in DS patients is up to 40%. Thus,
these proteins may play important roles in the
development of the disease. Fifteen relevant net-
works were constructed by MetaCore. The highest
scoring network was constituted by 6 proteins with
direct interaction. The PLMN was located in the cen-
ter of the network. However, the serum concentra-
tion from both mothers and patients showed no
significant change. But the reason for this needs to
be more deeply explored in future studies.
Regarding the 29 proteins we found in this study,
we think that it needs clinical verification whether
these proteins could be used for prenatal screen-
ing. Based on the study, we analyzed the charac-
terization of differential proteins by bioinformatics
analysis, and found something very interesting.
These proteins may play important roles in the
development of DS, for example mental retarda-
tion. They may help to explain the new mechanism
of the disease.
In conclusion, based on comparative proteomic
analysis, five significant differences of expressed
proteins in maternal serum between normal and
DS cases have been confirmed by ELISA. DAVID and
GeneGo MetaCore were used for bioinformatics
analysis of these candidate protein markers. The
combined use of ELISA and bioinformatics analy-
ses proved the different expression of the proteins,
and revealed their biological processes and func-
tional network in DS. These 29 proteins have rela-
tions with the development of Down syndrome,
especially CP and CFB play more important roles.
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